Tumor stroma-derived ANGPTL2 potentiates immune checkpoint inhibitor efficacy

Haruki Horiguchi,Tsuyoshi Kadomatsu,Tomoya Yamashita,Shinsei Yumoto,Taichi Horino,Michio Sato,Kazutoyo Terada,Keishi Miyata,Yuki Ichigozaki,Toshihiro Kimura,Satoshi Fukushima,Toshiro Moroishi,Yuichi Oike

DOI: https://doi.org/10.1038/s41417-024-00757-9

IF: 5.854

2024-03-12

Cancer Gene Therapy

Abstract:Use of immune checkpoint inhibitors (ICIs) as cancer immunotherapy has advanced rapidly in the clinic. We recently reported that tumor stroma-derived angiopoietin-like protein 2 (ANGPTL2) has tumor suppressive activity by enhancing dendritic cell-mediated CD8 + T cell anti-tumor immune responses. However, a direct impact of ANGPTL2 on ICI anti-tumor effect remains unclear. Here, we use a murine syngeneic model to show that host ANGPTL2 facilitates CD8 + T cell cross-priming and contributes to anti-tumor responses to ICIs in this context. Importantly, our analysis of public datasets indicated that ANGPTL2 expression is associated with positive responses to ICI therapy by human melanoma patients. We conclude that ANGPTL2-mediated stromal cell crosstalk facilitates anti-tumor immunity and ICI responsiveness. These findings overall provide novel insight into ANGPTL2 anti-tumor function and regulation of ICI-induced anti-tumor immunity.

oncology,genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology